Galecto Inc. is a biotechnology company focused on developing innovative therapies for fibrotic diseases and cancer

By leveraging its expertise in glycoscience, the company aims to create small molecule drugs that target specific pathological processes associated with these conditions. Galecto's research emphasizes the importance of the extracellular matrix in disease progression, and its pipeline includes candidates that seek to address critical unmet medical needs. The company's commitment to advancing scientific knowledge is coupled with a goal of improving patient outcomes through novel treatment options.